Chronic migraine: Definition, epidemiology, risk factors and treatment;Migraña crónica: Definición, epidemiología, factores de riesgo y tratamiento

Revista de Neurologia

Volumn 54, Issue 10, 2012, Pages 629-637

  Carod Artal, Francisco J ^a   Irimia, Pablo ^b   Ezpeleta, David ^c  

^a HOSPITAL VIRGEN DE LA LUZ   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c Neurology Service   (Spain)

Author keywords

Botulinum toxin; Chronic migraine; Disability; Epidemiology; Episodic migraine; Migraine; Topiramate

Indexed keywords

ANALGESIC AGENT; BOTULINUM TOXIN A; CAFFEINE; TOPIRAMATE;

ANXIETY; ARTICLE; DEPRESSION; DETOXIFICATION; DRUG USE; EDUCATIONAL STATUS; GENDER; HUMAN; INCIDENCE; MIGRAINE; OBESITY; PREVALENCE; RISK FACTOR; SLEEP APNEA SYNDROME; SNORING; SOCIAL STATUS;

EID: 84862197407     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5410.2012170     Document Type: Article

References (81)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2 ed. Cephalalgia 2004; 24 (Suppl 1): S9-160.
2. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-6.
3. Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache: analysis of factors. Headache 1982; 22: 66-8.
4. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996; 47: 871-5.
5. Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain 2011; 12: 593-601.
6. Pascual J, Sánchez del Río M, Jiménez MD, Láinez-Andrés JM, Mateos V, Leira R, et al. La migraña crónica vista por el neurólogo y el paciente: resultados del proyecto CIEN-MIG (III). Rev Neurol 2010; 50: 705-10.
7. Irimia P, Palma JA, Fernández-Torrón R, Martínez-Vila E. Migraña crónica y abuso de analgésicos. Rev Neurol 2010; 51: 703-4.
8. Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 2011; 15: 70-8.
9. Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 2011; 51 (Suppl 2): S77-83.
10. Castillo J, Muñoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190-6.
11. Katsarava Z, Dzagnidze A, Kukava M, Mirvelashvili E, Djibuti M, Janelidze M, et al. Lifting the burden: the global campaign to reduce the burden of headache Worldwide and the Russian Linguistic Subcommittee of the International Headache Society. Primary headache disorders in the Republic of Georgia: prevalence and risk factors. Neurology 2009; 73: 1796-803.
12. Da Silva A Jr, Costa EC, Gomes JB, Leite FM, Gomez RS, Vasconcelos LP, et al. Chronic headache and comorbibities: a two-phase, population-based, cross-sectional study. Headache 2010; 50: 1306-12.
13. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48: 1157-68.
14. Lipton RB, Manack A, Ricci JA, Chee E, Turkel CC, Winner P. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache 2011; 51: 693-706.
15. Gracia-Naya M, Alarcia-Alejos R, Modrego-Pardo PJ. Importancia de la migraña crónica en una consulta general de neurología. Rev Neurol 2008; 46: 577-81.
16. Schulman EA, Lake AE 3rd, Lipton RB. Refractory migraine: introductory editorial. Headache 2008; 48: 768-9.
17. Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011; 76: 1-8.
18. Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraneurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2010; 31: 301-15.
19. Lantéri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 2011; 31: 837-50.
20. Colás R, Muñoz P, Temprano R, Gómez C, Pascual J. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 2004; 62: 1338-42.
21. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008; 71: 559-66.
22. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre-clinical characteristics and treatment outcomes. Cephalalgia 2004; 24: 483-90.
23. Sánchez del Río-González M. Migraña crónica: fisiopatología. Rev Neurol 2012; 54 (Supl 2): S13-9.
24. Ashina S, Lyngberg A, Jensen R. Headache characteristics and chronification of migraine and tension-type headache: a population-based study. Cephalalgia 2010; 30: 943-52.
25. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010; 81: 428-32.
26. Guerrero-Peral AL. Migraña crónica: manifestaciones clínicas y diagnóstico diferencial. Rev Neurol 2012; 54 (Supl 2): S21-9.
27. Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache 2008; 48: 7-15.
28. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression (or for chronic daily headaches)-clinical lessons. Headache 2006; 46 (Suppl 3): S144-6.
29. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 2006; 67: 252-7.
30. Bigal ME, Lipton RB. What predicts the change from episodic to chronic migraine? Curr Opin Neurol 2009; 22: 269-76.
31. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343-9.
32. Carod-Artal FJ, Ezpeleta D, Martín-Barriga ML, Guerrero AL. Triggers, symptoms, and treatment in two populations of migraneurs in Brazil and Spain. A cross-cultural study. J Neurol Sci 2011; 304: 25-8.
33. Diener HC, Holle D, Dodick D. Treatment of chronic migraine. Curr Pain Headache Rep 2011; 15: 64-9.
34. Pascual J. Migraña crónica: tratamiento. Rev Neurol 2012; 54 (Supl 2): S31-8.
35. Pascual J, El Berdei Y, Gómez-Sánchez JC. How many migraine patients need prolonged (>1 year) preventive treatment? Experience with topiramate. J Headache Pain 2007; 8: 90-3.
36. Rains JC. Chronic headache and potentially modifiable risk factors: screening and behavioral management of sleep disorders. Headache 2008; 48: 32-9.
37. Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention Study. Headache 2012; 52: 3-17.
38. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45: 144-52.
39. Couch JR. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011; 51: 33-51.
40. Saper JR, Silberstein SD, Lake AE 3rd, Winters ME. Doubleblind trial of fluoxetine: chronic daily headache and migraine. Headache 1994; 34: 497-502.
41. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache 2006; 46: 1334-43.
42. Pascual J, Díaz-Insa S, Jurado C, Guerrero AL, González LCA. Migraña y migraña crónica. In Díaz-Insa S, ed. Guía oficial para el diagnóstico y tratamiento de las cefaleas 2011. Guías Oficiales de la Sociedad Española de Neurología. Barcelona: Prous Science; 2011. p. 43-75.
43. Leira R, Arjona A, Medrano V, Castro MD, Manso JC. Cefaleas secundarias I. In Díaz-Insa S, ed. Guía oficial para el diagnóstico y tratamiento de las cefaleas 2011. Guías Oficiales de la Sociedad Española de Neurología. Barcelona: Prous Science; 2011. p. 149-69.
44. Krymchantowski AV, Moreira PF. Out-patient detoxification in chronic migraine: comparison of strategies. Cephalalgia 2003; 23: 982-93.
45. Evers S, Jensen R. Treatment of medication overuse headache-guideline of the EFNS headache panel. Eur J Neurol 2011; 18: 1115-21.
46. Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephalalgia 2008; 28: 152-6.
47. Lake AE 3rd, Saper JR, Hamel RL. Comprehensive inpatient treatment of refractory chronic daily headache. Headache 2009; 49: 555-62.
48. Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache 2002; 42: 519-22.
49. Worz R, Berlin J. Behandlung chronischer Schmerzsyndrome mit Antidepressiva. Schmerz 1989; 3: 1-7.
50. Stillman MJ, Zajac D, Rybicki LA. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. Headache 2004; 44: 65-9.
51. Diener HC. Detoxification for medication overuse headache is not necessary. Cephalalgia 2011; Nov 29. [Epub ahead of print].
52. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 804-14.
53. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793-803.
54. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 814-23.
55. Silberstein SD. Migraine preventive treatment. Handb Clin Neurol 2011; 97: 337-54.
56. Silberstein S, Diener HC, Lipton R, Goadsby P, Dodick D, Bussone G, et al. Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache 2008; 48: 1087-95.
57. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003; 23: 820-4.
58. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-80.
59. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007; 47: 486-99.
60. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (Botox) for the prophylactic treatment of chronic daily headache: a randomized, doubleblind, placebo-controlled trial. Headache 2005; 45: 293-307.
61. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized doubleblind, placebo-controlled study. Headache 2005; 45: 315-24.
62. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, doubleblind, placebo-controlled trial. Mayo Clin Proc 2005; 80: 1126-37.
63. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-36.
64. Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, et al. Onabotulinumtoxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011; 51: 1358-73.
65. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxin A for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010; 50: 1406-18.
66. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119-28.
67. Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a doubleblind, placebo-controlled, multicenter outcome study. Headache 2002; 42: 470-82.
68. Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache 2008; 48: 1337-42.
69. Calandre EP, García-Leiva JM, Rico-Villademoros F, Vílchez JS, Rodríguez-López CM. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol 2010; 33: 35-9.
70. Pascual-Gómez J, Alañá-García M, Oterino A, Leira R, Láinez-Andrés JM. Tratamiento preventivo de la migraña crónica con zonisamida: un estudio en pacientes refractarios o intolerantes a topiramato. Rev Neurol 2008; 47: 449-51.
71. Pascual-Gómez J, Gracia-Naya M, Leira R, Mateos V, Álvaro-González LC, Hernando I, et al. Zonisamida en el tratamiento preventivo de la migraña refractaria. Rev Neurol 2010; 50: 129-32.
72. Calandre EP, Hidalgo J, García-Leiva JM, Rico-Villademoros F. Trigger point evaluation in migraine patients: an indication of peripheral sensitization linked to migraine predisposition? Eur J Neurol 2006; 13: 244-9.
73. García-Leiva JM, Hidalgo J, Rico-Villademoros F, Moreno V, Calandre EP. Effectiveness of ropivacaine trigger points inactivation in the prophylactic management of patients with severe migraine. Pain Med 2007; 8: 65-70.
74. Giamberardino MA, Tafuri E, Savini A, Fabrizio A, Affaitati G, Lerza R, et al. Contribution of myofascial trigger points to migraine symptoms. J Pain 2007; 8: 869-78.
75. Schoenen J, Allena M, Magis D. Neurostimulation therapy in intractable headaches. Handb Clin Neurol 2010; 97: 443-50.
76. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia 2010; 313: 271-85.
77. Lipton RB, Goadsby PJ, Cady RK, Aurora SK, Grosberg BM, Freitag F, et al. PRISM study: occipital nerve stimulation for treatment-refractory migraine. Cephalalgia 2009; 29 (Suppl 1): S30.
78. Silberstein S, Dodick D, Saper J, Huh B, Reed K, Narouze S, et al. The safety and efficacy of occipital nerve stimulation for the management of chronic migraine. Cephalalgia 2011; 31 (Suppl 1): S117.
79. Yang CP, Chang MH, Liu PE, Li TC, Hsieh CL, Hwang KL, et al. Acupuncture versus topiramate in chronic migraine prophylaxis: a randomized clinical trial. Cephalalgia 2011; 31: 1510-21.
80. Wang SJ, Young WB. Needling the pain and comforting the brain: acupuncture in the treatment of chronic migraine. Cephalalgia 2011; 31: 1507-9.
81. Pozo-Rosich P. Migraña crónica: epidemiología e impacto. Rev Neurol 2012; 54 (Supl 2): S3-11.